IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC
Posted: Thursday, September 23, 2021
The monoclonal antibody atezolizumab showed a significant improvement in disease-free survival among patients with stage II–IIIA non–small cell lung cancer (NSCLC) after surgical resection and adjuvant chemotherapy, in the IMpower010 trial. Now, in an exploratory analysis of this phase III trial, Nasser Altorki, MD, of NewYork-Presbyterian Hospital in New York City, and colleagues reported during a Plenary Session at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (Abstract PL02.05) that this benefit was seen regardless of the type of surgery of the chemotherapy doublet received.
“Patients who participated in the IMpower010 trial, including patients with nodal involvement, saw benefit across disease stages (stage II–IIIA subpopulations),” said Dr. Altorki in an IASLC press release.
This study enrolled 1,280 patients from 22 countries with fully resected stage Ib–IIIA NSCLC. In the intention-to-treat population, 78.1% had undergone lobectomy, 15.9% had pneumonectomy, and 5.0% underwent bilobectomy. Patients received a maximum of four 21-day cycles of cisplatin-based chemotherapy before being randomly assigned 1:1 to receive 1200mg of atezolizumab every 3 weeks or best supportive care. Most patients (76%–95%) in both arms received the planned cycles of chemotherapy.
According to Dr. Altorki, prerandomization variables (eg, the extent of pulmonary resection, the type of mediastinal nodal assessment, and adjuvant chemotherapy regimens), as well as the time from surgery to adjuvant treatment, are “topics of interest.” Mediastinal lymph node dissection or sampling was performed in 80.7% and 18.0% of patients, respectively.
Within the intention-to-treat population, the median time between surgery to the first treatment with atezolizumab or supportive care was 5.2 months and 5.1 months, respectively. Disease-free survival among both the population with 1% PD-L1 expression and the population with stage II–III1 NSCLC was improved with atezolizumab when compared with supportive therapy.
Disclosure: For disclosure information for the study authors, visit library.iaslc.org.
